General Information of Drug (ID: DMU9T3A)

Drug Name
1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)urea Drug Info
Synonyms CHEMBL27863; 1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)urea; SCHEMBL3705632; ZINC13559608; BDBM50140796
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9949456
TTD Drug ID
DMU9T3A

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [2]
Clotrimazole DMMFCIH Cutaneous candidiasis 1F23.14 Approved [3]
Reparixin DMVBA7I Pancreatic islet transplantation failure NE84 Phase 3 [2]
SCH-527123 DMPUAOE Chronic obstructive pulmonary disease CA22 Phase 2 [4]
SB-265610 DM8TKG5 Asthma CA23 Phase 2 [5]
AZD-5069 DM3JSFK Asthma CA23 Phase 2 [6]
PS-938285 DMHZIFJ Chronic obstructive pulmonary disease CA22 Phase 2 [7]
GSK1325756 DMA6RBF Chronic obstructive pulmonary disease CA22 Phase 2 [8]
SB-656933 DMCY785 Chronic obstructive pulmonary disease CA22 Phase 2 [9]
RIST4721 DMA3DKO Hidradenitis suppurativa ED92.0 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-X-C chemokine receptor type 2 (CXCR2) TT30C9G CXCR2_HUMAN Inhibitor [1]

References

1 Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1713-7.
2 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
3 Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
4 CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
5 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
6 Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
7 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
8 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
9 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
10 A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.